The following is an excerpt from an article in the LA Times today entitled “Why it’s risky to promise a coronavirus vaccine and cure”:
Author: ezra.marbach
The world of NAD+ supplements is confusing. This site is an effort to make sense of it. Please consider sharing it with others. If you have questions or comments, please email me. I respond promptly. Thank you for visiting.
Chromadex CEO Rob Fried appeared on the Adam Carolla Show to discuss his movie career, NAD+, Nicotinamide Riboside “NR” (FAQs) (Reviews), and COVID-19. Key quotes, podcast link, and video embedded below:
In the following interview excerpt, Dr Alyssa Dweck, an assistant professor at Mount Sinai explains NAD+ and when to start thinking about it:
A recent pre-clinical study showed that supplement Nicotinamide Riboside “NR” (FAQs) (Reviews) reduced hearing loss in mice. The lead scientist on the study commented:
Chromadex CEO Rob Fried appeared on the Habits and Hustle Podcast to discuss his movie career, NAD+, and Nicotinamide Riboside “NR” (FAQs) (Reviews). Key quotes, podcast link, and video embedded below:
Chromadex CEO Rob Fried appeared on the Optimal Performance Podcast to discuss NAD+ and Nicotinamide Riboside “NR” (FAQs) (Consumer Reviews). He shared some remarkable anecdotes about the impact of taking NR. Key quotes and podcast embedded:
Dr. Charles Brenner (FAQs), University of Iowa professor, chief scientific advisor at Chromadex, and discoverer of Nicotinamide Riboside “NR” (FAQs) (Reviews) as an NAD precursor vitamin joined the Ben Greenfield Fitness Podcast to discuss NAD+, NR, and lots more. Key quotes and podcast embedded:
Dr, Charles Brenner (FAQs), who discovered Nicotinamide Riboside “NR” (FAQs) (Reviews) as an NAD boosting vitamin joined the BulletProof Radio Podcast to discuss his latest research. Key quotes from the hour long interview:
Dr. Charles Brenner (FAQs), University of Iowa professor, chief scientific advisor at Chromadex, and discoverer of Nicotinamide Riboside “NR” (FAQs) as an NAD precursor vitamin recently responded to a number of investor questions. Key quotes: